<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1309">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685655</url>
  </required_header>
  <id_info>
    <org_study_id>S-911/2020</org_study_id>
    <nct_id>NCT04685655</nct_id>
  </id_info>
  <brief_title>RescuE pLAsma eXchange in Severe COVID-19</brief_title>
  <acronym>RELAX</acronym>
  <official_title>RescuE pLAsma eXchange in Severe COVID-19 (RELAX Severe COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The spectrum of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to&#xD;
      acute respiratory distress syndrome (&quot;ARDS&quot;) and patient death. Severely affected patients&#xD;
      may develop a cytokine storm-like clinical syndrome with high mortality. Laboratory tests in&#xD;
      these patients show an excessive and uncontrolled immune response with consecutive&#xD;
      multi-organ failure. In addition, there is evidence for the development of prothrombotic&#xD;
      autoantibodies as an epiphenomenon of &quot;Severe Acute Respiratory Syndrome Coronavirus 2&quot;&#xD;
      (SARS-CoV-2) infection. Therapeutic plasma exchange (&quot;TPE&quot;) is being discussed as a&#xD;
      therapeutic alternative in patients with severe, refractory COVID-19. The idea is that plasma&#xD;
      exchange eliminates both endogenous and exogenous inducers of an exuberant inflammatory&#xD;
      response as well as prothrombotic factors, thus breaking the secondary vicious circle of&#xD;
      SARS-CoV-2 infection. In general, TPE is a safe procedure with known efficacy in other severe&#xD;
      viral diseases as well as in cytokine storm-like diseases and ARDS of other geneses.&#xD;
      Moreover, initial data, mostly derived from case studies, demonstrate promising therapeutic&#xD;
      efficacy of TPE in severe COVID-19 courses with previously lacking treatment options. To&#xD;
      further evaluate the therapeutic efficacy of TPE in severe COVID-19, a prospective randomized&#xD;
      controlled trial of TPE in severe SARS-CoV-2 infection is being conducted at our center.&#xD;
      Patients will be randomized to a control group (standard therapy according to center&#xD;
      standards) and a therapy/intervention group (standard therapy + TPE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Therapeutic plasma exchange in patients with severe COVID 19</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>Intention to treat analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>15, 30, 60, 90, 365 days after randomization</time_frame>
    <description>Intention to treat &amp; per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>15, 30, 60, 90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital an ICU stay</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement defined as two points on seven point ordinal WHO scale</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of vasopressors after TPE treatments</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute kidney injury, renal replacement therapy and renal recovery</measure>
    <time_frame>15, 30, 60, 90 days after randomization</time_frame>
    <description>AKI KDIGO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of typical complications associated to therapeutic plasma exchange</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of inflammation mediators, (auto-)antibodies, and coagulation-associated molecules and their temporal correlation to TPE</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Therapeutic Plasma Exchange</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID-19 therapy according to center standard alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic plasma exchange and COVID-19 therapy according to center standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic plasma exchange</intervention_name>
    <description>Treatment with therapeutic plasma exchange. Plasma from healthy donors is used.</description>
    <arm_group_label>Therapeutic plasma exchange and COVID-19 therapy according to center standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent by the study participant or their legally appointed&#xD;
             representative.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Evidence of acute SARS-CoV-2 infection, confirmed by PCR testing&#xD;
&#xD;
          -  Invasive ventilation&#xD;
&#xD;
          -  Fever ≥ 38.5°C, confirmed by a total of 3 consecutive measurements or ongoing renal&#xD;
             replacement therapy&#xD;
&#xD;
          -  D-dimers ≥ 2mg/L&#xD;
&#xD;
          -  Dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 85 years&#xD;
&#xD;
          -  Pre-existing treatment limitations&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Confirmed pulmonary arterial embolism with hemodynamically relevant right heart strain&#xD;
&#xD;
          -  ST-segment elevation myocardial infarction (STEMI)&#xD;
&#xD;
          -  Participation in an intervention study elsewhere&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Nusshag, MD</last_name>
    <phone>+496221-5634952</phone>
    <email>Christian.Nusshag@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Morath, MD</last_name>
    <email>Christian.Morath@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Christian Nusshag</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Nusshag, MD</last_name>
      <phone>+4962215634952</phone>
      <email>Christian.Nusshag@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Christian Morath, MD</last_name>
      <email>Christian.Morath@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Nusshag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uta Merle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Morath, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus A. Weigand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Christian Nusshag</investigator_full_name>
    <investigator_title>MD, Attending, Department of Nephrology</investigator_title>
  </responsible_party>
  <keyword>Plasma exchange</keyword>
  <keyword>Covid19</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>On request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

